Maio Li Pan
Directeur/Membre du Conseil chez MingMed Biotechnology Co., Ltd.
Profil
Maio Li Pan is currently a Member-Supervisory Board at MingMed Biotechnology Co., Ltd.
Ms. Pan completed an undergraduate degree from Guangdong University of Technology in 2005.
Postes actifs de Maio Li Pan
| Sociétés | Poste | Début |
|---|---|---|
MingMed Biotechnology Co., Ltd.
 MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | Directeur/Membre du Conseil | 24/06/2022 |
Formation de Maio Li Pan
| Guangdong University of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | Health Technology |